EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australia: a cross-sectional survey study

Amanda Landers iD, Helen Brown, Juhaina Al Ruheili, Kylie Russell, Clare McKenzie, Meera R Agar, Vanessa M Yenson iD, Kate Clarke, John Windsor

Supportive Care in Cancer · 2024

DOI: 10.1007/s00520-024-08604-1 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Amanda Landers und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Otago, 2 Riccarton Ave, Christchurch Central, Christchurch, 8011, New Zealand. amanda.landers@otago.ac.nz. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Enzyme Replacement Therapy. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand, Canterbury Medical Research Foundation, University of Otago.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study investigated pancreatic enzyme replacement therapy (PERT) use in people diagnosed with pancreatic cancer in New Zealand (NZ) and Australia (AU).

Methods

A cross-sectional survey study was conducted using a mixed-media campaign to recruit people with pancreatic cancer and collect information about current PERT use. The questionnaire gathered data on participant demographics, awareness of PERT, prescribing practices and efficacy of enzyme replacement.

Results

Over 300 people with pancreatic cancer were recruited, 135 from New Zealand and 199 from Australia. Every region, state and territory was represented except for the West Coast (NZ) and the Northern Territory (AU), the lowest populated areas in both countries. In New Zealand, 60% of participants had heard about PERT, compared to 69.3% in Australia. Dosing regimens were inconsistent in both countries, with 18% and 27% of participants being prescribed PERT considered best practice in New Zealand and Australia, respectively. Before PERT commencement, 70% of participants experienced symptoms of malabsorption, with all symptoms improving after therapy was established. The majority of participants were compliant with their medication.

Conclusion

PERT use in pancreatic cancer in New Zealand and Australia was highly variable and not compliant with international guidelines in which PERT is recommended as standard therapy. Enzyme replacement is effective for improving the symptoms of malabsorption in patients with pancreatic cancer. Clinician education may be needed to help improve the use of PERT in people with pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsEnzyme Replacement TherapyHumansCross-Sectional StudiesNew ZealandFemaleMaleMiddle AgedAustraliaAgedSurveys and QuestionnairesAdultAged, 80 and over

Stichwörter der Autor:innen

Enzyme replacement therapyPancreatic cancerPancreatic exocrine insufficiencySymptom management

Autor:innen und Institutionen

  • Department of Medicine, University of Otago, 2 Riccarton Ave, Christchurch Central, Christchurch, 8011, New Zealand. amanda.landers@otago.ac.nz.
  • Nurse Maude Hospice Palliative Care Service, Nurse Maude Association, Christchurch, New Zealand.
  • Te Whatu Ora, Wellington, New Zealand.
  • Nutrition and Dietetics, Te Whatu Ora Te Toka Tumai, Auckland, New Zealand.
  • IMPACCT Centre, Faculty of Health, University of Technology Sydney, Sydney, Australia.
  • Surgical and Translational Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

ORCID-Profile: Amanda Landers, Vanessa M Yenson

Förderung

  • Health Research Council of New Zealand
  • Canterbury Medical Research Foundation
  • University of Otago

Zitieren

APA

Landers, A., Brown, H., Al Ruheili, J., Russell, K., McKenzie, C., Agar, M. R., Yenson, V. M., Clarke, K., & Windsor, J. (2024). Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australia: a cross-sectional survey study. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08604-1

Vancouver

Landers A, Brown H, Al Ruheili J, Russell K, McKenzie C, Agar MR, et al. Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australia: a cross-sectional survey study. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08604-1

BibTeX
@article{Landers2024,
  author = {Landers, Amanda and Brown, Helen and Al Ruheili, Juhaina and Russell, Kylie and McKenzie, Clare and Agar, Meera R and Yenson, Vanessa M and Clarke, Kate and Windsor, John},
  title = {Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australia: a cross-sectional survey study},
  journal = {Supportive Care in Cancer},
  year = {2024},
  doi = {10.1007/s00520-024-08604-1}
}
Kostenlos starten →